Beta2-adrenergic System and Training

NCT ID: NCT04616261

Last Updated: 2020-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-10

Study Completion Date

2022-11-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project aims to examine the trainability of the beta2-adrenergic system with respect to the individual performance response

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SET-HIGH

High volume speed endurance training

Group Type EXPERIMENTAL

Training

Intervention Type BEHAVIORAL

6 weeks of training

Formoterol

Intervention Type DRUG

inhalation of 54 microg formoterol

Placebo

Intervention Type DRUG

inhalation of placebo

SET-LOW

Low volume speed endurance training

Group Type EXPERIMENTAL

Training

Intervention Type BEHAVIORAL

6 weeks of training

Formoterol

Intervention Type DRUG

inhalation of 54 microg formoterol

Placebo

Intervention Type DRUG

inhalation of placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Training

6 weeks of training

Intervention Type BEHAVIORAL

Formoterol

inhalation of 54 microg formoterol

Intervention Type DRUG

Placebo

inhalation of placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 to 45 years of age
* Trained individuals with a maximal oxygen uptake above 55 ml/min/kg
* Body mass index lower than 26

Exclusion Criteria

* Allergy towards study drug
* Unacceptable side effects to the study drug
* Chronic disease deemed by the MD to interfere with the study
* Smoking
* Use of prescription medicine
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Copenhagen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Morten Hostrup, PhD

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FOREX

Identifier Type: -

Identifier Source: org_study_id